Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease ...

Dupixent may become the first targeted treatment for bullous pemphigoid ... bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical ...

such as Dupixent for the treatment of adults with bullous pemphigoid as discussed in this press release as well as chronic pruritus of unknown origin, lichen simplex chronicus, and other potential ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

The sBLA is based on data from a pivotal study that demonstrated that Dupixent led to significant improvements in sustained disease remission compared to placebo in adult patients with moderate-to ...

The sBLA is supported by data from a pivotal trial evaluating the efficacy and safety of Dupixent in 106 adults with moderate ... bullous pemphigoid, and lichen simplex chronicus.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Reducing stress and emotions and behavioral habits that damage skin, hair, or nails can enhance response to treatment ... herpes simplex, hyperhidrosis, lichen planus, lichen simplex chronicus ...

Treatments may relieve symptoms ... as this may contribute to a condition called lichen simplex chronicus which can further exacerbate the itching sensation There’s no single timeline for ...